{"organizations": [], "uuid": "8ccfc40045f6dfd06beefb25ae1053e740ff836c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/17", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/02/globe-newswire-pacific-biosciences-of-california-inc-announces-first-quarter-2018-financial-results.html", "country": "US", "domain_rank": 767, "title": "Pacific Biosciences of California, Inc. Announces First Quarter 2018 Financial Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-03T00:01:00.000+03:00", "replies_count": 0, "uuid": "8ccfc40045f6dfd06beefb25ae1053e740ff836c"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/02/globe-newswire-pacific-biosciences-of-california-inc-announces-first-quarter-2018-financial-results.html", "ord_in_thread": 0, "title": "Pacific Biosciences of California, Inc. Announces First Quarter 2018 Financial Results", "locations": [], "entities": {"persons": [], "locations": [{"name": "menlo park", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}], "organizations": [{"name": "nasdaq", "sentiment": "negative"}, {"name": "pacific biosciences of california, inc.", "sentiment": "neutral"}, {"name": "pacific biosciences of california, inc", "sentiment": "neutral"}, {"name": "pacb", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "MENLO PARK, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced financial results for its first quarter ended March 31, 2018.\nTotal revenue for the first quarter of 2018 was $19.4 million, compared to $24.9 million for the first quarter of 2017.\nGross profit for the first quarter of 2018 was $7.3 million, resulting in a gross margin of 38%. Gross profit for the first quarter of 2017 was $8.9 million, resulting in a gross margin of 36%.\nOperating expenses for the first quarter of 2018 totaled $31.2 million, compared to $32.2 million for the first quarter of 2017. Operating expenses for the first quarter of 2018 and 2017 included non-cash stock-based compensation of $4.6 million and $4.5 million, respectively.\nNet loss for the first quarter of 2018 was $24.2 million, compared to $23.9 million for the first quarter of 2017.\nCash, cash equivalents and investments, excluding restricted cash, at March 31, 2018 totaled $79.3 million, compared to $62.9 million at December 31, 2017.\nQuarterly Conference Call Information\nManagement will host a quarterly conference call to discuss its first quarter ended March 31, 2018 results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330,using an Audience Passcode of 936-7938. The call will be webcast live and will be available for replay at Pacific Biosciences’ website at http://investor.pacificbiosciences.com/ .\nAbout Pacific Biosciences\nPacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT ® ) Technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio ® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com .\nForward-Looking Statements\nAll statements in this press release that are not historical are , including, among other things, statements relating to the timeline for Pacific Biosciences’ potential development of products, future uses, quality or performance of, or benefits of using, products or technologies and other future events. You should not place undue reliance on because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.\nContact:\nTrevin Rard\n650.521.8450\nir@pacificbiosciences.com\nPacific Biosciences of California, Inc.\nUnaudited Condensed Consolidated Statement of Operations\n(amounts in thousands, except per share amounts) Quarter Ended March 31, 2018 2017 Revenue: Product revenue $ 16,282 $ 21,294 Service and other revenue 3,080 3,621 Total revenue 19,362 24,915 Cost of Revenue: Cost of product revenue 9,019 11,362 Cost of service and other revenue 3,047 4,616 Total cost of revenue 12,066 15,978 Gross profit 7,296 8,937 Operating Expense: Research and development 16,311 16,971 Sales, general and administrative 14,934 15,265 Total operating expense 31,245 32,236 Operating loss (23,949 ) (23,299 ) Interest expense (581 ) (838 ) Other income (expense), net 351 270 Net loss $ (24,179 ) $ (23,867 ) Basic and diluted net loss per share $ (0.20 ) $ (0.26 ) Shares used in computing basic and diluted net loss per share 123,768 92,970\nPacific Biosciences of California, Inc.\nUnaudited Condensed Consolidated Balance Sheets\n(amounts in thousands) March 31, December 31, 2018 2017 Assets Cash and investments $ 79,260 $ 62,872 Accounts receivable 8,452 13,433 Inventory 25,930 23,065 Prepaid and other current assets 2,057 2,249 Property and equipment 36,704 37,920 Long-term restricted cash 4,500 4,500 Other long-term Assets 46 45 Total Assets $ 156,949 $ 144,084 Liabilities and Stockholders' Equity Accounts payable $ 8,567 $ 9,093 Accrued expenses 10,243 12,618 Deferred service revenue 7,087 7,394 Deferred rent 14,285 14,453 Other liabilities 145 605 Financing derivative 12 183 Notes payable 13,872 13,635 Stockholders' equity 102,738 86,103 Total Liabilities and Stockholders' Equity $ 156,949 $ 144,084\nSource:Pacific Biosciences, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=rteea34r-L6wI0cPIYxBgJ9RtDLxMBCAyrdnUmkxaklHxm_BovOn_MFLGYfjNHsjEEJEfpaGgkwFB9tSAODubxBtF8A40QTUUslHdq_EodQ=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/6ee0cce4-5b97-455e-b36e-da7145a4453e", "https://www.globenewswire.com/Tracker?data=uQyEL4DG3JHP5frxIVvN4597auyW1X3LhuGgUrKJUalrqgxA27szaIWyCbbFw-0Zj6K1gp_gEmdvzItr8dCzcnWvlKoPOTCHsyhCFqGWK4FIc7MqDwYYxmdvuMIg0XgLAAxoRHflaWaU8Ze-yj-qig==", "http://investor.pacificbiosciences.com/", "https://www.globenewswire.com/Tracker?data=5jhwq37BwbzKrCwJDdLQ3CgabqvfrBisrBpzNHgX5vs91EjpZmmy-65zgYcW5rbqeTRiwiGI2e40pxFzDA-nfg=="], "published": "2018-05-03T00:01:00.000+03:00", "crawled": "2018-05-03T01:56:35.014+03:00", "highlightTitle": ""}